Sandoz Loses Bid To Invalidate IP In Toviaz Row With Pfizer
A Delaware federal judge on Wednesday upheld the validity of five patents licensed by Pfizer Inc. protecting its Toviaz overactive-bladder treatment, dealing a blow to Sandoz Inc. and other drug companies...To view the full article, register now.
Already a subscriber? Click here to view full article